A Pilot Study of Flumist, a Live Attenuated Intranasal Influenza Vaccine, and Inactivated Influenza Vaccine in Children With Cancer

Inclusion Criteria:

- Age 2 through 21 (not yet reached their 22nd birthday) at the time of entry into the
study

- Participant or participants parent/legal guardian available by telephone during the
course of the study;

- Written informed consent (and assent, if applicable) obtained

- Currently receiving chemotherapy and /or radiotherapy for the treatment of cancer or
have received chemotherapy in the past 12 weeks;

- If the participant's underlying cancer is a solid tumor, current status must be
stable disease, partial response, or complete response to therapy; if the
participant's underlying disease is a hematological malignancy, current status must
be in remission, and if receiving chemotherapy, must be in the "continuation" or
"maintenance" phase of therapy or equivalent;

- Estimated life expectancy of > 1 year

Exclusion Criteria:

- History of hypersensitivity to any component of FluMist or TIV, including egg or egg
products, gelatin, or monosodium glutamate;

- History of hypersensitivity to gentamicin;

- Close contact with a severely immunocompromised patient (e.g., a hematopoietic stem
cell transplant patient, during those periods in which the immunocompromised patient
requires care in a protective environment

- History of Guillain-Barre´ syndrome;

- History of asthma;

- Female who is breastfeeding or lactating;